Safety and Immunogenicity of Monovalent Omicron KP.2-Adapted BNT162b2 COVID-19 Vaccine in Adults: Single-Arm Substudy from a Phase 2/3 Trial.
Saved in:
| Title: | Safety and Immunogenicity of Monovalent Omicron KP.2-Adapted BNT162b2 COVID-19 Vaccine in Adults: Single-Arm Substudy from a Phase 2/3 Trial. |
|---|---|
| Authors: | Diya, Oyeniyi1 (AUTHOR), Gayed, Juleen1 (AUTHOR) juleen.gayed@pfizer.com, Lowry, Francine S.2 (AUTHOR), Ma, Hua2 (AUTHOR), Bangad, Vishva2 (AUTHOR), Mensa, Federico3 (AUTHOR), Zou, Jing4 (AUTHOR), Xie, Xuping4 (AUTHOR), Hu, Yanping4 (AUTHOR), Cutler, Mark5 (AUTHOR), Belanger, Todd5 (AUTHOR), Cooper, David5 (AUTHOR), Xu, Xia2 (AUTHOR), Mogg, Robin2 (AUTHOR), Türeci, Özlem3 (AUTHOR), Şahin, Uǧur3 (AUTHOR), Swanson, Kena A.5 (AUTHOR), Modjarrad, Kayvon5 (AUTHOR), Anderson, Annaliesa S.5 (AUTHOR), Gurtman, Alejandra5 (AUTHOR) |
| Source: | Infectious Diseases & Therapy. Aug2025, Vol. 14 Issue 8, p1973-1987. 15p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
